Stratatech's regenerative skin graft passes Phase II trial
Stratatech says its genetically -engineered skin substitute passed its Phase II clinical trial as a treatment for severe burns.
Wisconsin's Stratatech said its biologically active, genetically engineered skin substitute passed a Phase II clinical trial as a treatment for severe burns, setting the stage for a bid for a Phase III trial.
Stratatech Corp.News Well, Clinical Trials, Graft, Regenerative Medicineread more
Source: Mass Device - Category: Medical Equipment Authors: Mark Hollmer Source Type: news